Last reviewed · How we verify
Phase 1: Trabectedin
At a glance
| Generic name | Phase 1: Trabectedin |
|---|---|
| Sponsor | Institut Bergonié |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma (PHASE2)
- Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma (PHASE2)
- Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma (PHASE2)
- Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS (PHASE2)
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas (PHASE1)
- Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (PHASE2)
- Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (PHASE1)
- Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phase 1: Trabectedin CI brief — competitive landscape report
- Phase 1: Trabectedin updates RSS · CI watch RSS
- Institut Bergonié portfolio CI